Edgewise Therapeutics, Inc.

This study continues testing an experimental drug called sevasemten (EDG-5506) in people with Becker muscular dystrophy to see how safe it is over the long term. It's open to 260 adults and adolescents who have already participated in earlier studies of this same medication. Rese…

This study is testing whether a daily oral medication called EDG-5506 is safe and can help control muscle damage in children and teenagers with Duchenne muscular dystrophy who have already received gene therapy. About 43 participants aged 6-17 will take either the medication or a…

This study is testing an experimental drug called EDG-7500 in 100 adults with hypertrophic cardiomyopathy (HCM), a genetic condition where the heart muscle thickens and can cause serious symptoms. Researchers want to understand if different doses are safe and how they affect hear…

This study is testing an oral medication called EDG-5506 (sevasemten) in children with Duchenne muscular dystrophy (DMD), a serious muscle-wasting condition. Researchers want to see if the drug is safe, how it moves through the body, and if it can reduce signs of muscle damage. T…

This study is testing whether an investigational drug called sevasemten (EDG-5506) is safe and can help control the progression of Becker muscular dystrophy. It involves about 244 adults and adolescents with the condition, who will receive either the drug or a placebo for 12 to 1…